Brief: Vigil Neuroscience Inc Provided An Update On Company's Small Molecule Trem2 Agonist, Vg-3927

Vigil Neuroscience

12/10/2023 21:21

Oct 12 (Reuters) - Vigil Neuroscience Inc  VIGL.O :
    * VIGIL NEUROSCIENCE INC - PROVIDED AN UPDATE ON COMPANY'S
SMALL
MOLECULE TREM2 AGONIST, VG-3927
    * VIGIL NEUROSCIENCE - GOT 30-DAY RESPONSE LETTER FROM U.S.
FDA
REGARDING PREVIOUSLY COMMUNICATED PARTIAL CLINICAL HOLD ON IND
APPLICATION FOR VG-3927
    * VIGIL NEUROSCIENCE - LETTER SAYS EXTRA NON-CLINICAL DATA
NEEDS
TO BE PROVIDED TO EXCEED MAXIMUM EXPOSURE LIMIT IN PHASE 1 TRIAL
EVALUATING VG-3927
    * VIGIL NEUROSCIENCE INC - IN PROCESS OF OBTAINING
ADDITIONAL
PHARMACOKINETIC DATA AND WILL WORK WITH FDA TO ADDRESS PARTIAL
CLINICAL HOLD

Further company coverage:  VIGL.O 

 ((Reuters.Briefs@thomsonreuters.com;))